These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

956 related articles for article (PubMed ID: 30832741)

  • 1. Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau).
    Gibbons GS; Kim SJ; Robinson JL; Changolkar L; Irwin DJ; Shaw LM; Lee VM; Trojanowski JQ
    Acta Neuropathol Commun; 2019 Mar; 7(1):34. PubMed ID: 30832741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.
    Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY
    J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimer-related co-pathologies.
    Thal DR; von Arnim CA; Griffin WS; Mrak RE; Walker L; Attems J; Arzberger T
    J Neural Transm (Vienna); 2015 Jul; 122(7):1007-18. PubMed ID: 25556950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies.
    Pires G; McElligott S; Drusinsky S; Halliday G; Potier MC; Wisniewski T; Drummond E
    Acta Neuropathol Commun; 2019 Dec; 7(1):195. PubMed ID: 31796108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau).
    Dickson DW; Kouri N; Murray ME; Josephs KA
    J Mol Neurosci; 2011 Nov; 45(3):384-9. PubMed ID: 21720721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.
    Irwin DJ; Lleó A; Xie SX; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
    Ann Neurol; 2017 Aug; 82(2):247-258. PubMed ID: 28719018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent tau pathologies in frontotemporal lobar degeneration with TDP-43 pathology.
    Koga S; Zhou X; Murakami A; Fernandez De Castro C; Baker MC; Rademakers R; Dickson DW
    Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12778. PubMed ID: 34823271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL;
    Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies.
    Tagai K; Ono M; Kubota M; Kitamura S; Takahata K; Seki C; Takado Y; Shinotoh H; Sano Y; Yamamoto Y; Matsuoka K; Takuwa H; Shimojo M; Takahashi M; Kawamura K; Kikuchi T; Okada M; Akiyama H; Suzuki H; Onaya M; Takeda T; Arai K; Arai N; Araki N; Saito Y; Trojanowski JQ; Lee VMY; Mishra SK; Yamaguchi Y; Kimura Y; Ichise M; Tomita Y; Zhang MR; Suhara T; Shigeta M; Sahara N; Higuchi M; Shimada H
    Neuron; 2021 Jan; 109(1):42-58.e8. PubMed ID: 33125873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glial reactivity and T cell infiltration in frontotemporal lobar degeneration with tau pathology.
    Hartnell IJ; Woodhouse D; Jasper W; Mason L; Marwaha P; Graffeuil M; Lau LC; Norman JL; Chatelet DS; Buee L; Nicoll JAR; Blum D; Dorothee G; Boche D
    Brain; 2024 Feb; 147(2):590-606. PubMed ID: 37703311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.
    Lleó A; Irwin DJ; Illán-Gala I; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
    JAMA Neurol; 2018 Jun; 75(6):738-745. PubMed ID: 29554190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Level of PICALM, a key component of clathrin-mediated endocytosis, is correlated with levels of phosphotau and autophagy-related proteins and is associated with tau inclusions in AD, PSP and Pick disease.
    Ando K; Tomimura K; Sazdovitch V; Suain V; Yilmaz Z; Authelet M; Ndjim M; Vergara C; Belkouch M; Potier MC; Duyckaerts C; Brion JP
    Neurobiol Dis; 2016 Oct; 94():32-43. PubMed ID: 27260836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.
    Soleimani-Meigooni DN; Iaccarino L; La Joie R; Baker S; Bourakova V; Boxer AL; Edwards L; Eser R; Gorno-Tempini ML; Jagust WJ; Janabi M; Kramer JH; Lesman-Segev OH; Mellinger T; Miller BL; Pham J; Rosen HJ; Spina S; Seeley WW; Strom A; Grinberg LT; Rabinovici GD
    Brain; 2020 Dec; 143(11):3477-3494. PubMed ID: 33141172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Pathogenesis of the Tauopathies.
    Götz J; Halliday G; Nisbet RM
    Annu Rev Pathol; 2019 Jan; 14():239-261. PubMed ID: 30355155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration.
    Ghirelli A; Tosakulwong N; Weigand SD; Clark HM; Ali F; Botha H; Duffy JR; Utianski RL; Buciuc M; Murray ME; Labuzan SA; Spychalla AJ; Pham NTT; Schwarz CG; Senjem ML; Machulda MM; Baker M; Rademakers R; Filippi M; Jack CR; Lowe VJ; Parisi JE; Dickson DW; Josephs KA; Whitwell JL
    Ann Neurol; 2020 Nov; 88(5):1009-1022. PubMed ID: 32869362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF tau microtubule-binding region identifies pathological changes in primary tauopathies.
    Horie K; Barthélemy NR; Spina S; VandeVrede L; He Y; Paterson RW; Wright BA; Day GS; Davis AA; Karch CM; Seeley WW; Perrin RJ; Koppisetti RK; Shaikh F; Lago AL; Heuer HW; Ghoshal N; Gabelle A; Miller BL; Boxer AL; Bateman RJ; Sato C
    Nat Med; 2022 Dec; 28(12):2547-2554. PubMed ID: 36424467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective tau tyrosine nitration in non-AD tauopathies.
    Reyes JF; Geula C; Vana L; Binder LI
    Acta Neuropathol; 2012 Jan; 123(1):119-32. PubMed ID: 22057784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response.
    Thal DR; Del Tredici K; Ludolph AC; Hoozemans JJ; Rozemuller AJ; Braak H; Knippschild U
    Acta Neuropathol; 2011 Nov; 122(5):577-89. PubMed ID: 21935637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Argyrophilic grain disease and Alzheimer's disease are distinguished by their different distribution of tau protein isoforms.
    Tolnay M; Sergeant N; Ghestem A; Chalbot S; De Vos RA; Jansen Steur EN; Probst A; Delacourte A
    Acta Neuropathol; 2002 Oct; 104(4):425-34. PubMed ID: 12200631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixed TDP-43 proteinopathy and tauopathy in frontotemporal lobar degeneration: nine case series.
    Kim EJ; Brown JA; Deng J; Hwang JL; Spina S; Miller ZA; DeMay MG; Valcour V; Karydas A; Ramos EM; Coppola G; Miller BL; Rosen HJ; Seeley WW; Grinberg LT
    J Neurol; 2018 Dec; 265(12):2960-2971. PubMed ID: 30324308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.